{"denomUnitsSelected":"Participants","description":"As assessed by the number and grade of serious and non-serious adverse events, graded according to CTCAE v5.0","reportingStatus":"NOT_POSTED","timeFrame":"until 5 months post last IMP administration","title":"Safety and Tolerability of Pembrolizumab and Rituximab as Assessed by the Frequency of Serious and Non-serious Adverse Events, According to CTCAE v5.0","type":"SECONDARY"}